Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid by Fritsch, C et al.
Photodynamic therapy (PDT) with d-aminolaevulinic acid (ALA)
is based on the administration of ALA, the non-fluorescent first
committed compound in the pathway of haem biosynthesis, to the
diseased skin (Kennedy et al, 1990). Thus, ALA-synthase is
bypassed and porphyrins as photosensitizers are formed, preferen-
tially in neoplastic tissues. Subsequent light irradiation of the
sensitized tissue leads to reactive species-induced tumour necrosis
by targeting biological membranes (Pass, 1993) and by vascular
damage with subsequent tumour cell anoxia (Goetz et al, 1990).
In dermatology, topical ALA-PDT has been used to treat
precancerous lesions and neoplasms of the skin without serious
adverse effects (Fritsch et al, 1996b). High efficacy of ALA-PDT
was achieved for solar keratoses, superficial basal cell carcinomas,
and superficial squamous cell carcinomas (Kennedy et al, 1990;
Wolf et al, 1993; Calzavara-Pinton, 1995; Fritsch et al, 1996a,
1997d). In addition, there are also reports that psoriatic plaques
can be beneficially treated with ALA-PDT (Boehncke et al, 1994;
Stringer et al, 1996).
The presence of high intralesional porphyrin levels is important
for effective ALA-PDT. The amount of newly formed porphyrins
depends on the application time of ALA. Distribution studies using
porphyrin fluorescence revealed maximum fluorescence in
tumours up to 24h after topical or systemical administration of
ALA (Kennedy et al, 1990; Abels et al, 1994; Szeimies et al, 1994;
Martin et al, 1995; Peng et al, 1995; Kriegmair et al, 1996).
However, biochemical data on the absolute levels of porphyrin
metabolites, which have been determined in untreated skin (Goerz
et al, 1995), are lacking for ALA-treated lesions. In addition, the
time-point of maximum porphyrin accumulation is still not exactly
known for specific cutaneous lesions. Therefore, we examined the
time-dependent formation of porphyrins after topical application of
ALA in epithelial skin tumours, psoriatic lesions and normal skin.
MATERIALS
Tissue samples used were: basal cell carcinomas (BCC; n= 32),
squamous cell carcinomas (SCC; n= 32), psoriatic lesions (PS; n=
32), normal skin (NS; n= 160). Tumour samples were obtained
from patients who underwent surgery. Psoriatic tissue samples
were taken by punch biopsy for histopathological examination and
analysis of the porphyrin pattern.
Normal skin was examined: (a) from patients with tumours or
psoriasis which were treated with ALA and (b) from subjects free
of tumour or psoriasis. Tissue samples of normal skin from
patients with tumours or psoriasis were either taken from the
tumour- or psoriasis-adjacent site (NS-A) or from locations distant
from the lesions (NS-D) = individual controls. Additionally,
normal skin samples (NS) were obtained from patients free of
BCC, SCC or PS = interindividual controls (Table 1). This study
design was chosen to investigate the influence of the proximity of
normal skin to neoplastic or psoriatic skin on ALA-induced
porphyrin accumulation. Each patient received comprehensive
information about the scope of the study.
METHODS
ALA-treatment and photodynamic diagnosis (PDD)
Pilot studies on topical ALA application (up to 80mg cm–2) to
normal skin revealed plateau porphyrin levels (approximately
4nmol g–1 protein) > 40mg ALA cm–2 (data not shown). Based on
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Correspondence to:  C Fritschthese data and due to clinical experience in ALA-PDT (Calzavara-
Pinton, 1995; Wolf et al, 1993) an ALA (hydrochloride) mixture
of 20% was prepared in an ointment (Neribas®, Schering, Berlin,
Germany). Of the 20% ALA mixture, 0.2 g (40 mg ALA cm–2)
were applied to a 1-cm2 skin area of BCC, SCC, psoriatic lesions,
and all normal skin lesions. Treated skin was covered with an
occlusive foil (Tegaderm®, 3M Healthcare, Borken, Germany),
gauze, aluminium foil and tape to enhance tissue penetration and
avoid photobleaching of the formed porphyrins. After defined incu-
bation times (1, 2, 4, 6, 9, 12 and 24 h) the tape and the ointment
were removed and the treated area was illuminated with
Wood’s light (Fluotest®, Xenotest, Hanau, Germany; 370–405 nm).
Fluorescence intensity was measured and expressed semiquantita-
tively according to a fluorescence standard as 0 (no), 1 (low), 2
(medium) and 3 (strong fluorescence). The fluorescent area was
marked. Basal values were obtained from untreated controls.
According to our clinical experience, BCC and SCC reveal a
strong, homogeneous, ALA-induced porphyrin fluorescence under
Wood’s light (Figure 1A) (Fritsch et al, 1996a, 1997b), whereas
about 20–40% of psoriatic lesions show areas with inhomoge-
neous or absent fluorescence (Figure 1B). For better comparison
of intralesional porphyrin formation in PS and tumours, we
selected only uniform fluorescing psoriatic areas for our study.
Biochemical analysis was also performed in nonfluorescing
psoriatic areas (n = 8) which were treated with ALA for 6 h.
Preparation of skin samples
Only superficial layers of skin samples (< 1 mm) were included in
the study due to the limited penetration of topically applied ALA
(Szeimies et al, 1994; Martin et al, 1995; Peng et al, 1995).
Immediately after excision tissue samples were frozen in liquid
nitrogen and stored at – 80°C until further examination.
Determination of total porphyrin and protein levels in
tissues
Tissue samples were weighed and cut into small pieces. After
homogenization with an Ultraturrax and centrifugation at
3000 U min–1 for 10 min, porphyrins were isolated with 1.0 N
perchloric acid/methanol (1/1, v/v). In the supernatant, the total
porphyrin level was assessed by fluorescence spectroscopy
(Perkin Elmer LS-5, Überlingen, Germany); emission was
recorded in a range of 520–700 nm at an excitation wavelength of
405 nm (Soret band). For quantification a protoporphyrin standard
(Porphyrin Products Inc., Logan, Utah, USA) was used (Fritsch et
al, 1997a). Protein levels were determined in the pellet according
to Lowry et al (1951).
Determination of porphyrin metabolites in tissues
The supernatant was adjusted with acetic acid to pH 3–4,
porphyrins were bound to talcum, esterified and metabolites were
identified by HPLC with fluorescence detection (L-7480, Merck
Hitachi, Darmstadt, Germany) using a porphyrin standard mixture
(Porphyrin Products Inc., Logan, Utah, USA) for quantification
(Seubert and Seubert, 1982). The following metabolites were
analysed: protoporphyrin, tricarboxylic porphyrin, copropor-
phyrin, pentacarboxylic porphyrin, hexacarboxylic porphyrin,
heptacarboxylic porphyrin and uroporphyrin. The last four
porphyrin metabolites are designated as highly carboxylated
porphyrins; data are given as the sum of these compounds.
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Table 1 Design of the study: selection of normal skin samples
Samples from
Sample from the same patient other patients
Disease Adjacent to lesion Distant from lesion No lesion
Lesion NS-A NS-D NS
nnn n
BCC 32 16 16
SCC 32 16 16 32
Psoriasis 32 32 32
BCC, basal cell carcinoma; SCC, squamous cell carcinoma; PS, psoriasis lesion; NS-A, normal skin adjacent to lesion; NS-D, normal skin distant from lesion;
NS, normal skin in patients free of lesions. Normal skin samples were taken from patients whose tumours or psoriatic lesions were also treated by ALA. One
part of these samples was adjacent to the lesions (NS-A) and one part distant to the lesions (NS-D). In addition, normal skin samples were examined in other
patients which were not yet included for tumours or psoriasis (NS). Thus, the neoplastic lesions had individual and interindividual controls of normal skin.
Table 2 Fluorescence intensities of tissues treated by 20% ALA
1h 2h 4h 6h 9h 1 2h 2 4h
NS 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 1.3 ± 0.2 1.5 ± 0.3 1.5 ± 0.3 1.5 ± 0.3
BCC 2.8 ± 0.2 2.6 ± 0.2 2.8 ± 0.2 2.9 ± 0.1 2.6 ± 0.2 2.8 ± 0.2 2.5 ± 0.2
SCC 2.8 ± 0.2 2.5 ± 0,3 3.0 ± 0 2.8 ± 0.2 2.5 ± 0.3 2.5 ± 0.3 2.3 ± 0.2
Psoriasis 1.3 ± 0.2 1.8 ± 0.4 2.8 ± 0.2 2.8 ± 0.2 2.5 ± 0.3 2.5 ± 0.3 1.5 ± 0.3
Fluorescence intensities of ALA-treated skin irradiated by Wood’s light (370–405 nm, 10-cm distance, 5 mW cm–2). Values are given according to a fluorescence
standard: 0 = no fluorescence, 3 = maximum fluorescence (n = 4; mean ± s.e.m.). Normal skin (NS) was observed in patients free of tumours and psoriasis. NS,
BCC, SCC or PS not treated by ALA did not show any fluorescence.Statistical calculation
Statistical analysis of the data was performed by Student’s t-test.
Data are reported as mean ± SEM. Changes were considered statis-
tically significant when P < 0.05.
RESULTS
Fluorescence intensities of treated tissues
The highest macroscopic fluorescence intensities were found in
BCC, SCC and PS 4–6 h after ALA application. At all time-points
normal skin (NS) revealed only slight fluorescence intensities
compared with neoplastic and psoriatic skin (Table 2).
Basal total porphyrin levels in BCC, SCC, PS and skin
(all)
In untreated tissues (basal values), the levels of total porphyrins
were similarly low in normal skin, tumours and psoriasis (Figure 2).
Total porphyrin levels in BCC, SCC, PS and skin after
topical application of ALA
ALA application induced porphyrin synthesis in all tissues. The
porphyrin levels in BCC and SCC showed maximum values
between 2 h (53.8 ± 19.3 and 46.8 ± 17.3) and 6 h (60.0 ± 13.4 and
49.4 ± 13.1 nmol mg–1 protein). The highest porphyrin accumula-
tion was measured in psoriatic lesions with 91.7 ± 14.4 nmol mg–1
protein at 6 h. Normal skin samples: in NS and NS-D, the accumu-
lation of ALA-induced porphyrins was comparably low with a
maximum at 24 h (15.6 ± 6.6 nmol mg–1 protein) (Figure 2); at 6 h,
NS-A close to tumours or PS showed higher porphyrin levels
(23.8 ± 4.0 and 19.1 ± 4.1 nmol mg–1 protein) than NS or normal
skin distant from lesions (NS-D). The ratio of porphyrins measured
in BCC vs NS (BCC/NS) showed maximum values between 1 and
6 h (4.8–5.5) (Figure 3). The maximum ratio of porphyrins SCC/NS
(4.8–5.1) was observed 1–4 h after ALA-application. In PS, there
was the most distinct maximum of the porphyrin ratio to NS with
7.0 after 6 h. However, using normal skin adjacent to tumours of PS
(NS-A) as reference, the ratios of porphyrin levels in lesions vs skin
were much lower; maximum values were measured after 2 h for
BCC (3.7), after 4 h for SCC (3.3) and after 6 h for PS (4.8).
Basal porphyrin metabolite levels in BCC, SCC, PS and
NS (all)
The pattern of porphyrin metabolites was comparable in all
untreated tissues with protoporphyrin as the predominant
metabolite (82.9–92.3%) followed by uroporphyrin (all tissues)
(4.6–6.2%), heptacarboxylic porphyrin (NS: 0.9% and PS: 1.5%),
and coproporphyrin (BCC: 2.7% and SCC: 3.9%).
Porphyrin metabolite patterns in BCC, SCC, PS and NS
(all) after topical application of ALA
The pattern of metabolites was not changed following ALA-treat-
ment. Protoporphyrin was still the predominant metabolite and
ALA-induced porphyrin biosynthesis in skin tumours and psoriasis 1605
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Figure 1 Lesions treated for 6 h with 20% ALA and illuminated with Wood’s
light. Black dotted lines indicate the areas treated by ALA. (A) BCC showing
a homogeneous bright red fluorescence of porphyrins formed intralesionally.
Tumour-surrounding tissue treated by ALA also shows fluorescence though
less intense, impressing as whitish or pale pink. (B) Psoriatic lesion with
stippled bright fluorescent areas indicating non-uniform sensitization with
porphyrins
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Figure 2 Porphyrin levels in BCC, SCC, PS, NS adjacent to tumours [NS-A
(BCC and SCC)], NS adjacent to PS [NS-A (PS)] and NS of patients not
included for ALA treatment of tumour or psoriasis. In all tumour and psoriatic
tissues, the maximum porphyrin accumulation was detected at 4–6 h after
ALA application (*P < 0.005 BCC, SCC, PS vs NS). NS-A showed higher
porphyrin levels than NS obtained from patients free of lesions, respectively
(†P < 0.05). Porphyrin levels in NS distant from lesions (NS-D) were not
different from those measured in NS (data are not included in the figure).
Mean ± s.e.m. [n = 4; except NS-A (BCC, SCC): n = 8 for each data point]
A
Baccumulated in all tissues over a period of 24 h (Figure 4A and B).
Only at 1 h was there a slight decrease in protoporphyrin and a
slight increase in the highly carboxylated porphyrins. At the time-
point of the maximum ratio of porphyrins in BCC/NS, SCC/NS or
PS/NS (1–12 h, 6 h), protoporphyrin was the prevailing metabolite
in the lesions (Table 3, Figure 4A and B).
DISCUSSION
In the present study the time course of porphyrin metabolite
formation in human skin after topical application of ALA was
investigated. The maximum levels of porphyrins in epithelial
tumours and psoriatic lesions had already been detected at 1–6 h
after application of ALA. This indicates that ALA is rapidly
absorbed by the damaged skin and abnormal cells, and subse-
quently converted to porphyrins. In NS and NS-D, porphyrin
sensitization was less than in BCC, SCC or PS but prolonged,
indicating temporary skin photosensitivity. The higher porphyrin
levels in NS-A than in NS (Figure 2) may be due to the leakage of
porphyrins from the lesions into the surrounding tissues. This
phenomenon may be relevant with respect to PDT efficacy
because the tumour-nutrifying tissue is an additional target in
therapy (Goetz et al, 1990).
Comparing porphyrin levels in lesions with that in NS (Figures
2 and 3), optimum efficacy of topical ALA-PDT may be expected
if irradiation of BCC and SCC is performed between 1 and 6 h,
and of PS at 6 h, after ALA treatment.
In general, the available data on ALA-induced porphyrin levels
in human tissues are based on fluorescence studies (Warloe et al,
1992; Svanberg et al, 1994; Szeimies et al, 1994; Malik et al,
1995; Martin et al, 1995; Peng et al, 1995; Stringer et al, 1996)
(Table 4) and only some biochemical studies were performed
(Fritsch et al, 1997c, 1998). It was shown by fluorescence
microscopy that the major factor limiting the efficacy of topical
ALA-PDT is the penetration depth of ALA and ALA-induced
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Table 3 Total porphyrin levels and distribution of porphyrin metabolites 6 h after topical application of 20% ALA
Total Proto- Tricarboxylic Copro- Pentacarboxylic Hexacarboxylic Heptacarboxylic Uro-
porphyrins porphyrin porphyrin porphyrin porphyrin porphyrin porphyrin porphyrin
(nmol g–1 protein) (%) (%) (%) (%) (%) (%) (%)
NS 4.7 ± 0.8 88.3 ± 2.8 0 ± 0 0.6 ± 0.5 0 ± 0 0.7 ± 0.4 4.0 ± 0.9 7.9 ± 1.3
BCC 15.7 ± 1.1* 92.2 ± 1.2 0 ± 0 2.1 ± 0.6 0 ± 0 0.6 ± 0.3 1.1 ± 0.4 5.3 ± 1.3
SCC 16.7 ± 2.1* 92.6 ± 1.7 0 ± 0 1.9 ± 0.7 0 ± 0 0.4 ± 0.3 3.6 ± 1.1 7.1 ± 1.6
PS 21.9 ± 2.7* 83.8 ± 7.6 0 ± 0 1.5 ± 1.3 0.5 ± 0.4 2.1 ± 1.3 4.3 ± 2.7 8.9 ± 2.5
Data are given as nmol porphyrin g–1 protein (n = 4; mean ± s.e.m.; *P < 0.005). Porphyrin patterns showed no significant differences between tumours,
psoriasis and normal skin.
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Figure 3 Ratios of total porphyrin levels BCC/NS (filled bars), SCC/NS
(dotted bars), PS/NS (empty bars) after topical application of 20% ALA.
Distinct maximum for PS/NS after 6 h. Comparable maximum levels for
BCC/NS and SCC/NS between 1 and 4 h
Figure 4 Distribution of porphyrin metabolites in BCC and NS after topical
application of 20% ALA. Protoporphyrin (filled circles), coproporphyrin (open
squares), highly carboxylated porphyrins (penta-, hexa-, heptacarboxylic
porphyrin, uroporphyrin) (open triangles). (A) In BCC, protoporphyrin was the
prevailing metabolite (*P < 0.001 vs coproporphyrin and the highly
carboxylated porphyrin metabolites) (mean ± s.e.m.; n = 8 for each data
point). (B) For NS, a slight decrease of protoporphyrin levels 1 h after ALA
application was detected (*P < 0.001 and # < 0.01 vs coproporphyrin and the
highly carboxylated porphyrin metabolites) (mean ± s.e.m.; n = 4 for each
data point)
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Bporphyrins, which is dependent on the incubation time of ALA, the
combination with additives and the kind of skin surface treated. In
the case of BCC, the penetration was limited to a depth of about
0.75–0.81 mm (Martin et al, 1995; Peng et al, 1995) and could be
enhanced by addition of dimethylsulphoxide (DMSO) and ethyl-
enediaminetetraacetic acid disodium salt (EDTA) (up to 1.25 mm).
Long-time application of ALA together with 4% EDTA for
20–48 h increased the homogeneity of fluorescence distribution,
particularly at the bottom of the lesions (Peng et al, 1995).
Fluorescence studies on the kinetics of the ALA-induced
porphyrins showed maximum levels in BCC and PS 4–6 h after
ALA application with 3–15-fold higher levels than in normal skin
(Svanberg et al, 1994; Stringer et al, 1996). These data are
supported by our analysis.
In the psoriatic skin samples which showed no fluorescence 6 h
after ALA application, we found no higher porphyrin levels
(22.4 ± 8.2 nmol g–1 protein) than in NS-A. The hyperkeratotic
psoriatic areas with limited penetration of ALA may be one reason
for the inhomogeneous accumulation of porphyrins, similarly to
verrucae vulgares (Fritsch et al, 1997b). The correlation of fluores-
cence intensity under Wood’s light with the porphyrin levels
suggests that the clinical evaluation of the fluorescence gives an
orientation on superficial intralesional porphyrin levels. This
method is already used in photodynamic diagnosis (PDD), a novel,
effective diagnostic modality in tumour detection and demarcation
(Figure 1) (Fritsch et al, 1996a, 1997b, 1997d; Kriegmair et al,
1996).
In the present study no striking differences between basal and
ALA-induced porphyrin metabolite patterns were found with
protoporphyrin as the predominant compound (Table 3). Inhibition
of mitochondrial ferrochelatase, which forms haem by incorpora-
tion of iron into protoporphyrin, might decrease haem availability
for negative feedback control. This could explain the accumulation
of protoporphyrin in tumour and psoriatic tissue, analogous
to cells from patients who suffer from erythropoietic proto-
porphyria (Bloomer et al, 1977). It might be that the normal
kinetics of ferrochelatase in epithelial cells, which are most
probably responsible for porphyrin synthesis in epithelial
neoplasms, are rate-limiting for the entire pathway, and that by
supplying an overwhelming quantity of upstream substrate (ALA),
protoporphyrin is predominantly accumulated.
The route of ALA administration and the presence of serum
proteins may be relevant for increased formation of additional
porphyrins such as copro- and uroporphyrin, which was demon-
strated in a hamster melanoma (Fritsch et al, 1997a), in skin organ
cultures (keratoakanthoma, BCC and NS) (Fritsch et al, 1997c)
and various cell lines incubated with FCS-containing medium
(Hanania et al, 1992; Bolsen et al, 1996).
In the case of topical ALA-application, the accumulation of
higher levels of total porphyrins in tumours and psoriasis lesions
appears to be the major effect responsible for the intralesional photo-
sensitization. Our biochemical data show that the porphyrin metabo-
lite patterns are not significantly changed upon ALA treatment.
Intravenous injection or oral administration of ALA was shown
to optimize the homogeneous intralesional accumulation of
porphyrins in PS, BCC and oral cavity SCC (Grant et al, 1993;
Peng et al, 1995; Stringer et al, 1996). In mice or rats bearing colon
or mammary carcinomas and in hamsters bearing an amelanotic
melanoma, systemically administered ALA led to earlier (1 h) and
higher tumour/skin ratios (6–30) of porphyrins than did topical
ALA application (Peng et al, 1992; Hua et al, 1995; Sroka et al,
1996; Fritsch et al, 1997a). However, prolonged accumulation of
porphyrins in the liver following intravenous injection of ALA was
detected (Fritsch et al, 1997a) which may be responsible for
reported side effects such as nausea, vomiting or transient increases
in serum aspartate aminotransferase (Regula et al, 1994; Peng et al,
1995). Thus, topical application of ALA seems to be still the most
promising technique in PDT of epithelial skin tumours due to lack
of severe side effects (Fritsch et al, 1996b). PDT efficacy may be
enhanced using ALA esters (Fritsch et al, 1998).
After topical application of ALA (for PDD or PDT), light avoid-
ance for 2 days is recommended due to the prolonged porphyrin
sensitization of normal skin, which lasts up to 48 h with decreasing
intensity (data not shown). Psoriatic lesions may not offer
ALA-induced porphyrin biosynthesis in skin tumours and psoriasis 1607
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Table 4 Studies on kinetics of ALA-induced porphyrins in various tissues after topical application of ALA
Ratio
Human/ ALA Scale Max. Max. Pre-treatment
animals Tissue (%) Additive (h) (h) (h) value Tissues levels (h) Method Author
Human BCC 20 EDTA 3–48 29–48 n.d. n.d. n.d. n.d. FM Peng et al, 1995
BCC 20 – 4–6 n.d. 4–6 15 Tumour/skin n.d. LIF Svanberg et al, 1994
PS 20 – 1.5–180 4–6 4–6 3–10 Psoriasis/skin < 180 LIF Stringer et al, 1996
BCC 20 – 1–24 6 1–4 4.8–5.5 Tumour/skin > 24 SP / HPLC This study
SCC 20 – 1–24 4 1–4 4.8–5.1 Tumour/skin > 24 SP / HPLC This study
PS 20 – 1–24 6 6 17 Psoriasis/skin > 24 SP / HPLC This study
Mice NS 20 – 1–14 14 – – – n.d. LIF Peng et al, 1996
SCC 20 – 2–24 10 10 4.5 Tumour/skin 24 F/FM Veen et al, 1996
Mamma Ca* 20 – 1–5 3 3 0.2 Tumour/skin n.d. SP Peng et al, 1992
Colon Ca* 20 EDTA 2–6 6 n.d. 0.4 Tumour/skin n.d. LIF/SP Malik et al, 1995
DMSO
Rat Bladder Ca 50 mg – 4–24 4 4 2 Tumour / skin or 24 FM linuma et al, 1995
Tumour/Bladder
Pig NS 20 – 0.5–3 3 – – – n.d. F Goff et al, 1992
*, Subcutaneously growing tumours; Ca, carcinoma; Pre-treatment levels, time-point after ALA-application which was reported to show comparable porphyrin
levels prior to ALA treatment; LIF, laser-induced fluorescence analysis; FM, fluorescence microscopy F, fluorescence detection under excitation with UV/visible
light; SP, spectrophotometry of extracted porphyrins; HPLC, high performance liquid chromatography; n.d. = no data.optimum conditions for topical ALA-PDT and should be selected
according to the fluorescence pattern under Wood’s light.
ABBREVIATIONS
ALA, d-aminolaevulinic acid; BCC, basal cell carcinoma; DMSO,
dimethylsulphoxide; EDTA, ethylenediaminetetraacetic acid; NS,
normal skin; NS-A, normal skin adjacent to tumour or psoriasis
lesion; NS-D, normal skin distant from tumour or psoriasis lesion;
PDD, photodynamic diagnosis; PDT, photodynamic therapy; PS,
psoriasis; SCC, squamous cell carcinoma
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